DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled ...
Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...
The updated labeling provides a new conversion chart for starting dosages when switching patients from subcutaneous mealtime insulin to Afrezza. The Food and Administration (FDA) has approved updated ...
TUCSON, Ariz. (KGUN) — Diabetics have many options nowadays for their treatment plans. Afrezza is FDA-approved for adults with type 1 or type 2 diabetes as a fast-acting, mealtime insulin, but it ...
ORLANDO, Fla. — The inhaled insulin Afrezza combined with a long-acting basal analog offers a non-inferior insulin treatment option for people with type 1 diabetes, new phase 4 data suggest. Afrezza ...
MannKind Corporation recently enrolled the first pediatric patient in its INHALE-1ST trial and previously had an FDA supplemental Biologics License Application for Afrezza inhaled insulin in children ...
Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1D Data to be featured ...
(RTTNews) - MannKind Corporation (MNKD) has enrolled the first patient in INHALE-1ST, a pediatric clinical study evaluating the early initiation of Afrezza (insulin human) Inhalation Powder in youth ...
Afrezza (insulin human) is a brand-name inhaled insulin prescribed to manage blood sugar in adults with diabetes. It comes as a powder that you typically take at mealtimes. The dosage can vary based ...
MannKind’s fair value estimate is held at US$7.50, signaling that the core price target framework is intact even as some ...
Broadcast spot recognized at 2018 Medical Marketing & Media (MM&M) Awards WESTLAKE VILLAGE, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), a company focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results